JonesTrading analyst Soumit Roy has maintained their bullish stance on TARA stock, giving a Buy rating on October 15.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Soumit Roy has given his Buy rating due to a combination of factors surrounding Protara Therapeutics’ promising developments. The company is poised for significant advancements with its TARA-002 asset, particularly in the high-risk, BCG-Unresponsive non-muscle invasive bladder cancer (NMIBC) setting. Upcoming regulatory clarifications and clinical data expected in late 2025 and early 2026 are anticipated to build positive momentum for the company.
Additionally, Protara’s TARA-002 has demonstrated competitive efficacy and a clean safety profile, albeit in a small patient population. With key competitors closing enrollment for their trials, Protara may experience faster patient recruitment. Furthermore, the company’s assets in pediatric lymphatic malformations and IV choline present additional opportunities. The former is expected to follow a smoother path to approval, while the latter is seen as a de-risked, late-stage asset. These factors collectively contribute to the optimistic outlook and the Buy rating.
According to TipRanks, Roy is an analyst with an average return of -18.4% and a 24.49% success rate. Roy covers the Healthcare sector, focusing on stocks such as Protara Therapeutics, CervoMed, and CG Oncology, Inc..
In another report released on October 15, LifeSci Capital also maintained a Buy rating on the stock with a $26.00 price target.